Document is current
Any future updates will be listed below
-
Authors
Matuszek, Zaneta https://orcid.org/0000-0001-5627-0593
Arbab, Mandana https://orcid.org/0000-0001-9216-5096
Kesavan, Maheswaran
Hsu, Alvin https://orcid.org/0000-0003-4034-2788
Roy, Jennie C. L.
Zhao, Jing
Yu, Tian
Weisburd, Ben https://orcid.org/0000-0001-9898-9109
Newby, Gregory A.
Doherty, Neil J.
Wu, Muzhou
Shibata, Shota https://orcid.org/0000-0002-9131-5408
Cristian, Ana
Tao, Y. Allen
Fearnley, Liam G. https://orcid.org/0000-0003-2198-5411
Bahlo, Melanie https://orcid.org/0000-0001-5132-0774
Rehm, Heidi L. https://orcid.org/0000-0002-6025-0015
Xie, Jun
Gao, Guangping https://orcid.org/0000-0003-0097-9012
Mouro Pinto, Ricardo https://orcid.org/0000-0001-6744-2805
Liu, David R. https://orcid.org/0000-0002-9943-7557
- License Information
-
More Information
Article History
Received: 24 July 2024
Accepted: 18 March 2025
First Online: 26 May 2025
Change Date: 20 June 2025
Change Type: Update
Change Details: In the version of the article initially published, an earlier, incorrect version of the Supplementary Tables was included. The correct file is now available online.
Competing interests
: Z.M., M.A. and D.R.L. have filed patent applications on this work. D.R.L. is a consultant, co-founder and/or equity owner of Beam Therapeutics, Prime Medicine, Pairwise Plants and nChroma Bio, companies that use or deliver genome or epigenome editing agents. The other authors declare no competing interests.
